Ampio Pharmaceuticals (AMPE) 10-K 27 Mar 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Mar. 22, 2023	Jun. 30, 2022
Document And Entity Information [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-35182
Entity Registrant Name	AMPIO PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-0179592
Entity Address, Address Line One	373 Inverness Parkway
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Englewood
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80112
City Area Code	720
Local Phone Number	437-6500
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	AMPE
Security Exchange Name	NYSEAMER
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 37.3
Entity Common Stock, Shares Outstanding		15,102,877
Auditor Name	Moss Adams LLP
Auditor Location	Denver, Colorado
Auditor Firm ID	659
Entity Central Index Key	0001411906
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Amendment Flag	false

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 12,653,000	$ 33,892,000
Prepaid expenses and other	676,000	1,740,000
Total current assets	13,329,000	35,632,000
Fixed assets, net	184,000	2,564,000
Right-of-use asset, net	75,000	629,000
Total assets	13,588,000	38,825,000
Current liabilities
Accounts payable and accrued expenses	852,000	4,811,000
Lease liability-current portion	340,000	311,000
Total current liabilities	1,192,000	5,122,000
Lease liability-long-term	274,000	614,000
Warrant derivative liability	44,000	5,805,000
Asset retirement obligation	289,000	0
Total liabilities	1,799,000	11,541,000
Commitments and contingencies (Note 6)
Stockholders' equity
Preferred Stock, par value $0.0001; 10,000,000 shares authorized; none issued
Common Stock, par value $0.0001; 300,000,000 shares authorized; shares issued and outstanding - 15,102,877 as of December 31, 2022 and 15,172,111 as of December 31, 2021	2,000	2,000
Additional paid-in capital	245,726,000	244,884,000
Accumulated deficit	(233,939,000)	(217,602,000)
Total stockholders' equity	11,789,000	27,284,000
Total liabilities and stockholders' equity	$ 13,588,000	$ 38,825,000

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical)	Dec. 31, 2022 $ / shares shares	Dec. 31, 2021 $ / shares shares
Balance Sheets
Preferred Stock, par value | $ / shares	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Common Stock, par value | $ / shares	$ 0.0001	$ 0.0001
Common Stock, shares authorized	300,000,000	300,000,000
Common Stock, shares issued	15,102,877	15,172,111
Common Stock, shares outstanding	15,102,877	15,172,111

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expenses
Research and development	$ 8,916,000	$ 11,900,000
General and administrative	11,466,000	8,671,000
Long-lived assets impairment	1,614,000	0
Right of use asset impairment	322,000	0
Total operating expenses	22,318,000	20,571,000
Other income
Interest income	220,000	4,000
Derivative gain	5,761,000	3,492,000
Total other income	5,981,000	3,496,000
Net loss	$ (16,337,000)	$ (17,075,000)
Net loss per common share: Basic	$ (1.08)	$ (1.29)
Net loss per common share: Diluted	$ (1.47)	$ (1.51)
Weighted average number of common shares outstanding: Basic	15,072,308	13,286,605
Weighted average number of common shares outstanding: Diluted	15,072,308	13,664,202

Statements of Stockholders' Equ

Statements of Stockholders' Equity - USD ($)	Common Stock At The Market Equity Offering Program	Common Stock	Additional Paid-in Capital At The Market Equity Offering Program	Additional Paid-in Capital	Accumulated Deficit At The Market Equity Offering Program	Accumulated Deficit	At The Market Equity Offering Program	Total
Beginning Balance at Dec. 31, 2020		$ 2,000		$ 218,041,000		$ (200,527,000)		$ 17,516,000
Beginning Balance, Shares at Dec. 31, 2020		12,909,017
Issuance of common stock for services		$ 0		80,000		0		80,000
Issuance of common stock for services (Shares)		3,604
Share-based compensation, net of forfeitures		$ 0		2,724,000		0		2,724,000
Stock options exercised, net		$ 0		120,000		0		120,000
Stock options exercised, net (Shares)		25,774
Shares held back in settlement of tax obligation for shares issued in connection with restricted stock awards		$ 0		(186,000)		0		(186,000)
Shares held back in settlement of tax obligation for shares issued in connection with restricted stock awards (Shares)		(7,572)
Warrants exercised, net		$ 0		114,000		0		114,000
Warrants exercised, net (Shares)		39,215
Shares issued in connection with restricted stock awards		$ 0		0		0		0
Shares issued in connection with restricted stock awards (Shares)		119,000
Issuance of common stock in connection with the "at-the-market" equity offering program	$ 0		$ 10,511,000		$ 0		$ 10,511,000
Issuance of common stock in connection with the "at-the-market" equity offering program (Shares)	416,406
Issuance of common stock and warrants in connection with the registered direct offering		$ 0		22,497,000		0		22,497,000
Issuance of common stock and warrants in connection with the registered direct offering (Shares)		1,666,667
Offering costs related to the issuance of common stock in connection with the "at-the-market" equity offering program		$ 0		(512,000)		0		(512,000)
Offering costs related to the issuance of common stock and warrants in connection with the registered direct offering		0		(1,816,000)		0		(1,816,000)
Fair value related to the issuance of warrants in connection with the registered direct offering		0		(6,689,000)		0		(6,689,000)
Net loss		0		0		(17,075,000)		(17,075,000)
Ending Balance at Dec. 31, 2021		$ 2,000		244,884,000		(217,602,000)		27,284,000
Ending Balance, Shares at Dec. 31, 2021		15,172,111
Share-based compensation, net of forfeitures		$ 0		1,462,000		0		1,462,000
Shares held back in settlement of tax obligation for shares issued in connection with restricted stock awards		$ 0		(79,000)		0		(79,000)
Shares held back in settlement of tax obligation for shares issued in connection with restricted stock awards (Shares)		(9,234)
Offering costs related to the issuance of common stock and warrants in connection with the registered direct offering		$ 0		(32,000)		0		(32,000)
Restricted stock award forfeitures				(509,000)				(509,000)
Restricted stock award forfeitures (Shares)		(60,000)
Net loss		$ 0		0		(16,337,000)		(16,337,000)
Ending Balance at Dec. 31, 2022		$ 2,000		$ 245,726,000		$ (233,939,000)		$ 11,789,000
Ending Balance, Shares at Dec. 31, 2022		15,102,877

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows used in operating activities
Net loss	$ (16,337,000)	$ (17,075,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation, net of forfeitures	1,462,000	2,724,000
Restricted stock award compensation, forfeitures	(509,000)	0
Issuance of common stock for services	0	80,000
Depreciation and amortization	1,048,000	1,094,000
Long-lived assets impairment	1,614,000	0
Right of use asset impairment	322,000	0
Accretion of asset retirement obligation	7,000	0
Derivative gain	(5,761,000)	(3,492,000)
Changes in operating assets and liabilities:
Decrease (increase) in prepaid expenses and other	1,064,000	(593,000)
(Decrease) increase in accounts payable and accrued expenses	(3,959,000)	3,262,000
Decrease in lease liability	(79,000)	(89,000)
Net cash used in operating activities	(21,128,000)	(14,089,000)
Cash flows used in investing activities
Purchase of fixed assets	0	(97,000)
Net cash used in investing activities	0	(97,000)
Cash flows (used in) provided by financing activities
Proceeds from sale of common stock in connection with the "at-the-market" equity offering program	0	10,512,000
Costs related to sale of common stock in connection with the "at-the-market" equity offering program	0	(512,000)
Proceeds from sale of common stock and warrants in connection with the registered direct offering	0	22,500,000
Costs related to the sale of common stock and warrants in connection with the registered direct offering	(32,000)	(1,816,000)
Proceeds from warrant and stock option exercises, net	0	234,000
Funding of tax obligation relative to shares withheld in connection with restricted stock awards	(79,000)	(186,000)
Net cash (used in) provided by financing activities	(111,000)	30,732,000
Net change in cash and cash equivalents	(21,239,000)	16,546,000
Cash and cash equivalents at beginning of period	33,892,000	17,346,000
Cash and cash equivalents at end of period	12,653,000	33,892,000
Non-cash transactions:
Commercial insurance premium financing agreement	1,159,000	1,016,000
Recognition of asset retirement obligation	$ 282,000	$ 0

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2022
Basis of Presentation
Basis of Presentation	Note 1 – Basis of Presentation The accompanying financial statements have been prepared in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”). Ampio Pharmaceuticals, Inc. (“Ampio” or “the Company”) is a pre-revenue stage biopharmaceutical company, located in Englewood, CO, that is currently focused on the preclinical development of AR-300 and currently conducting studies to evaluate the efficacy of AR-300 in osteoarthritis related pain. The Company’s core activities relate to research and development and raising capital. The Company has not generated operating revenue to date. On November 9, 2022, the Company effected a 15-to-1 reverse stock split. The Company has retroactively applied the reverse stock split made effective on November 9, 2022 to share and per share amounts in the consolidated financial statements as of December 31, 2022 and December 31, 2021. Additionally, pursuant to their terms, a proportionate adjustment was made to the per share exercise price and number of shares issuable under all of the Company’s outstanding options and warrants, and the number of shares authorized for issuance pursuant to the Company’s equity incentive plans have been reduced proportionately, with any fractional shares rounded up to the next whole share. The Company also retroactively applied such adjustments in the notes to the consolidated financial statements as of December 31, 2022 and December 31, 2021. The reverse stock split did not reduce the number of authorized shares of common stock and preferred stock and did not alter the par value.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and related disclosures in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions primarily include the Company’s projected current and long-term liquidity, the clinical trial accrual, projected useful lives and potential impairment of long-lived assets and ROU asset (“right-of-use asset”). The Company develops these estimates using its judgment based upon the facts and circumstances known at the time. Cash and Cash Equivalents The Company considers instruments purchased with an original maturity of three months or less to be cash equivalents. The Company’s investment policy is to preserve principal and maintain liquidity. On March 10, 2023, the Federal Deposit Insurance Corporation (“FDIC”) placed Silicon Valley Bank (SVB) into receivership. At that time, the Company held approximately in a deposit account at SVB. The balance of the Company’s cash was held in an investment account that is not a deposit account and therefore, these amounts would not be impacted by the FDIC’s receivership of SVB or subject to FDIC insurance limits. Following the joint statement by the U.S. Treasury, Federal Reserve and the FDIC on March 12, 2023, the Company regained access to all of its deposit account funds. The Company refined its cash management strategy in order to further mitigate the potential risk of loss associated with deposit accounts balances in excess of the FDIC insured amount. Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts or foreign currency hedging arrangements. The Company consistently maintains its cash and cash equivalent balances in the form of bank demand deposits, United States federal government backed treasury securities and liquid money market fund accounts with financial institutions that management believes are creditworthy. The Company periodically monitors its cash positions with, and the credit quality of, the financial institutions with which it invests. During the years ended December 31, 2022 and 2021, the Company has maintained balances in excess of federally insured limits. Fixed Assets Fixed assets are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals and the related cost required to get certain equipment in operating condition. The Company charges routine and ongoing maintenance and repairs to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of property and equipment is depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the remaining life of the lease. Impairment of Long-Lived Assets The Company performs an evaluation on an annual basis, or sooner if management believes a triggering event has occurred, of the recoverability related to the carrying value of its long-lived assets to determine if facts and circumstances indicate that the carrying value of assets may be impaired and if any adjustment is warranted. The Company recorded impairment charges of $1.6 million and $0.3 million on its long-lived and ROU assets, respectively, during the year ended December 31, 2022. No impairment existed for long-lived or ROU assets Fair Value of Financial Instruments The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses, and warrant derivative liability. The carrying amounts of cash and cash equivalents, accounts payable and accrued expenses are carried at cost, which approximates fair value due to the short maturity of these instruments. The warrant derivative liability is recorded at estimated fair value based on utilization of the Black-Scholes warrant pricing model depending on facts and circumstances. See Note 7 and Note 8 Share-Based Compensation The Company accounts for share-based payments by recognizing compensation expense based upon the estimated fair value of the share-based payments on the date of grant. The Company determines the estimated fair value of the share-based payments granted using the fair market value or Black-Scholes option pricing model and recognizes compensation costs ratably over the requisite service period which approximates the vesting period using the graded method. See Note 10 Income Taxes Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a valuation allowance against all of its net deferred tax assets, as management has concluded that it is more likely than not that the net deferred tax asset will not be realized through projected future taxable income, based primarily on the Company’s ongoing history of operating losses and the lack of taxable income in the foreseeable future. See Note 11 Research and Development Research and development costs are expensed as incurred in the respective periods. Liquidity The company recognized a net loss of $16.3 million, which is primarily attributable to operating expenses of $22.3 million, partially offset by the non-cash derivative gain of $5.8 million (see Note 8 Over this period, we have continued to be focused on research and pre-clinical / clinical drug development all of which has required raising a substantial amount of capital. ​ Recently, we announced that we completed clinical trial reports for all legacy Ampion trials and submitted those reports to the appropriate agencies for review and ultimate publication on Clinical Trials.gov. In addition, we also informed the FDA that we have discontinued further development of the product and withdrawn the INDs. The combination of these activities concludes the development efforts on Ampion. ​ In addition, we have continued to focus on reducing operating costs, including but not limited to, the reduction of personnel expense to correspond to the conclusion of development efforts relating to Ampion and have engaged a nationally recognized commercial real estate broker to assist with sublease of the existing office space. As previously stated, we are currently conducting preclinical studies to evaluate the safety and efficacy of AR-300 with the initial target for treatment of OAK. ​ Adoption of Recent Accounting Pronouncements The Company has not adopted any recent accounting pronouncements during the year ended December 31, 2022, as none were deemed to be applicable. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standard Board (the “FASB”) issued ASU 2020-06, “ Debt (Subtopic 470-20); Debt with Conversion and Other Options and Derivatives and Hedging (Subtopic 815-40) Contracts in Entity’s Own Equity This Annual Report on Form 10-K does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures. ​

Prepaid Expenses and Other

Prepaid Expenses and Other	12 Months Ended
	Dec. 31, 2022
Prepaid Expenses and Other
Prepaid Expenses and Other	Note 3 – Prepaid Expenses and Other Prepaid expenses and other balances as of December 31, 2022 and 2021 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 ​ December 31, 2021 ​ ​ ​ ​ ​ ​ ​ Unamortized commercial insurance premiums ​ $ 610,000 ​ $ 465,000 Deposits ​ ​ 34,000 ​ ​ 884,000 Professional fees ​ ​ 19,000 ​ ​ 235,000 Clinical trial inventory ​ ​ — ​ ​ 72,000 Other ​ ​ 13,000 ​ ​ 84,000 Total prepaid expenses and other ​ $ 676,000 ​ $ 1,740,000 ​

Fixed Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2022
Fixed Assets
Fixed Assets	Note 4 – Fixed Assets Fixed assets balances, net of accumulated depreciation, as of December 31, 2022 and 2021 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Estimated ​ ​ ​ ​ ​ ​ ​ ​ Useful Lives ​ ​ ​ (in Years) December 31, 2022 ​ December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Leasehold improvements 10 ​ $ 4,965,000 ​ $ 6,075,000 Manufacturing facility/clean room 3 - 8 ​ 2,803,000 ​ 2,984,000 Lab equipment and office furniture 5 - 8 ​ 1,661,000 ​ 1,739,000 Fixed assets, gross ​ ​ ​ ​ 9,429,000 ​ ​ 10,798,000 Accumulated depreciation ​ ​ ​ ​ (9,245,000) ​ ​ (8,234,000) Fixed assets, net ​ ​ ​ $ 184,000 ​ $ 2,564,000 ​ In accordance with ASC Topic 360, Property, Plant and Equipment, the Company assesses all of its long-lived assets for impairment when impairment indicators are identified. Based on the assessment at September 30, 2022, the Company recorded a non-cash impairment related to its long-lived assets which was triggered by the Company’s announcement during the current reporting period that it was discontinuing further development of its lead pipeline asset, Ampion. The Company utilized a market valuation approach for determining the fair value of the ROU asset and a combination of the indirect cost approach and market approach for determining the fair value of the long-lived fixed assets. Based on this analysis, we concluded that the carrying value of the assets exceeded its undiscounted cash flows, and, as such, an impairment loss, calculated as the difference between carrying value and fair value, was deemed necessary. Accordingly, the Company recorded a $1.6 million impairment loss during the third quarter of 2022 as a direct reduction to the cost basis of the affected assets. ​ Depreciation expense as of December 31, 2022 and 2021 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 2021 ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization expense ​ $ 1,048,000 ​ $ 1,094,000 ​ ​

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2022
Accounts Payable and Accrued Expenses
Accounts Payable and Accrued Expenses	Note 5 – Accounts Payable and Accrued Expenses Accounts payable and accrued expenses as of December 31, 2022 and 2021 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 ​ December 31, 2021 ​ ​ ​ ​ ​ Accounts payable ​ $ 97,000 ​ $ 427,000 Clinical trials ​ ​ 89,000 ​ ​ 2,995,000 Professional fees ​ 157,000 ​ 510,000 Commercial insurance premium financing ​ 189,000 ​ 269,000 Accrued severance ​ ​ 143,000 ​ ​ — Accrued compensation ​ ​ — ​ ​ 389,000 Other ​ ​ 177,000 ​ ​ 221,000 Accounts payable and accrued expenses ​ $ 852,000 ​ $ 4,811,000 ​ ​ Commercial Insurance Premium Financing Agreement ​ In June 2022, the Company entered into an insurance premium financing agreement for $1.2 million, with a term of eight months and an annual interest rate of 3.98% and made a down payment of $402,000 . Under the terms and provisions of the agreement, the Company is required to make principal and interest payments totaling $95,000 per month over the remaining term of the agreement. The outstanding obligation of $189,000 as of December 31, 2022 was paid in full in February 2023. ​

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Litigation.
Commitments and Contingencies	Note 6 – Commitments and Contingencies Key Clinical Research Trial Obligations Osteoarthritis of the Knee ​ ​ ​ AP-013 study In December 2020, the Company entered into an initial contract with a clinical research organization (“CRO”) in reference to the AP-013 study totaling $1.4 million. The contractual provisions required a retainer of $315,000, which was applied to study expenses as further defined by the contract. The Company entered into change orders to the initial contract in February 2022 totaling $0.2 million and April 2022 totaling $0.7 million which reflected the final costs to close out the study. The Company had an outstanding future contractual commitment of $120,000 (net of the $315,000 deposit) as of December 31, 2021. As of December 31, 2022, trial activities and related services have been completed and, as such, there is no commitment for future services. Inhaled treatment for COVID-19 patients AP-018 study and AP-019 study In March 2021, the Company entered into a contract with a CRO totaling $318,000 in reference to a Phase 1 study for at-home treatment utilizing inhaled Ampion to treat patients with Long-COVID, or prolonged respiratory symptoms due to COVID-19 (the “AP-018 study”). Subsequent to March 2021, the Company agreed to a contractual amendment totaling $946,000 resulting in a total contractual commitment of $1.3 million. As of December 31, 2022, trial activities and related services have been completed and, as such, there is no commitment for future services. In June 2021, the Company entered into a contract with a CRO totaling $2.6 million in reference to a multicenter Phase 2 clinical trial, using inhaled Ampion in the treatment of respiratory distress due to COVID-19 (the “AP-019 study”). The contractual amount was subsequently amended by $0.9 million resulting in a total contractual commitment of $3.5 million. The AP-019 study has been completed as of December 31, 2022 and, as such, there is no commitment for future services. Intravenous (“IV”) treatment for COVID-19 patients AP-017 study In December 2020, the Company entered into a contract with a CRO totaling $1.8 million in reference to a multicenter Phase 2 clinical trial utilizing IV Ampion in the treatment of patients with COVID-19 requiring oxygen supplementation (the “AP-017 study”). The Company stopped the trial after an interim analysis which reflected enrollment of 35 subjects and resulted in a favorable net contractual adjustment and revised contractual commitment of $0.5 million and $1.3 million, respectively. The AP-017 study was completed as of December 31, 2022 and, as such, there is no commitment for future services. Employment Agreements As of December 31, 2022, the Company is a party to an employment agreement dated October 11, 2021 with Daniel Stokely to serve as the Company’s Chief Financial Officer with a term ending in October 2024 and at an initial base salary of $335,000. On August 30, 2022, the Company amended the existing employment agreement, originally dated November 22, 2021 that specified an initial base salary of $550,000, with Michael A. Martino to serve as the Company’s Chief Executive Officer. The employment term was extended to November 22, 2023. All other terms and conditions of Mr. Martino’s employment agreement remain unchanged. Under these employment agreements, each executive is entitled to a severance payment in the event the Company terminates employee’s employment without cause, or employee terminates his employment with good reason. ​ Related Party Research Agreements On February 4, 2022, the Company entered into a sponsored research services agreement with Trauma Research, LLC, an entity owned by one of the Company’s former directors. The agreement totaled $400,000 for research activities to be performed over the next two years . In addition, the Company also entered into a personal services agreement dated February 4, 2022 with that individual to provide research services. The agreement totaled $250,000 and was to be paid in four equal installments payable quarterly over the one-year term. On August 5, 2022, the Company delivered notice of termination of the personal services agreement, effective September 5, 2022 and during September paid the remaining obligation of $21,000 . On August 5, 2022, the Company delivered notice of termination of the research services agreement, effective November 4, 2022, and paid the remaining obligation of $63,000 . Facility Lease In December 2013, the Company entered into a 125-month non-cancellable operating lease for office space and a manufacturing facility, set to expire September 2024 with the right to renew for an additional 60 months. The effective date of the lease was May 1, 2014. The initial base rent of the lease was $23,000 per month. The total base rent over the term of the lease is approximately $3.3 million, which includes rent abatements and leasehold incentives. In accordance with the provisions of the lease agreement, the Company is legally obligated to dismantle and remove certain components of leasehold improvements at the end of the lease term. (See also Note 15 Asset Retirement Obligations, The Company adopted the FASB issued ASC 842, “Leases (Topic 842)” obligation represents the Company’s commitment to make the lease payments arising from the lease. ROU lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company’s lease does not provide an implicit rate, the Company used an estimated incremental borrowing rate of 5.75%, based on the information available at the commencement date in determining the present value of the lease payments. Lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. The lease liability is classified as both current in part and long-term on the balance sheet. The following table provides a reconciliation of the Company’s remaining undiscounted payments for its facility lease and the carrying amount of the lease liability presented in the balance sheet as of December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Facility Lease Payments 2023 2024 2025 2026 2027 Thereafter ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Remaining Facility Lease Payments ​ $ 644,000 ​ $ 364,000 ​ $ 280,000 ​ $ — ​ $ — ​ $ — ​ $ — Less: Discount Adjustment ​ (30,000) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total lease liability ​ $ 614,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Lease liability-current portion ​ $ 340,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Long-term lease liability ​ $ 274,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The Company reviews the potential for impairment of the ROU asset consistent with the approach applied to other long-lived assets. ROU assets are reviewed for recoverability whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment loss is recorded for the excess of the asset’s carrying amount over its fair value. Accordingly, the Company recorded a $0.3 million impairment loss on the right-of-use asset, recorded in operating expenses and against the ROU asset, during the year ended December 31, 2022. The following table provides a reconciliation of the Company’s remaining ROU asset for its facility lease presented in the balance sheet as of December 31, 2022: ​ ​ ​ ​ ​ ​ ROU Asset ​ ​ ​ Balance as of December 31, 2021 ​ $ 629,000 Amortization ​ ​ (232,000) Impairment loss ​ ​ (322,000) Balance as of December 31, 2022 ​ $ 75,000 ​ The Company recorded lease expense in the respective periods is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 2021 ​ ​ ​ ​ ​ ​ ​ ​ Lease expense ​ $ 311,000 ​ $ 275,000 ​ ​

Warrants

Warrants	12 Months Ended
	Dec. 31, 2022
Warrants.
Warrants	Note 7 – Warrants The Company has issued both equity (“placement agent”) and liability classified (“investor”) warrants in conjunction with equity raises. The Company had a total of 0.1 million equity-classified warrants and 1.0 million liability-classified warrants outstanding as of December 31, 2022. The following table summarizes the Company’s warrant activity: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Weighted Average ​ ​ Number of ​ Average ​ Remaining ​ ​ Warrants ​ Exercise Price ​ Contractual Life ​ ​ ​ ​ ​ ​ ​ ​ Outstanding as of December 31, 2021 ​ 1,220,194 ​ ​ $ 15.36 ​ 4.24 Warrants expired ​ (155,057) ​ ​ $ 11.40 ​ ​ Outstanding as of December 31, 2022 1,065,137 ​ ​ $ 15.94 3.80 ​ The following table summarizes the Company’s outstanding warrants between placement agent and investor warrant classifications: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Weighted Average ​ ​ ​ ​ ​ ​ ​ Number of ​ Average ​ Remaining Date ​ Exercise Price ​ Type ​ Warrants ​ Exercise Price ​ Contractual Life ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 2021 registered direct offering ​ ​ $ 16.50 ​ Investor ​ 1,000,000 ​ ​ ​ ​ 3.96 August 2018 public offering ​ ​ $ 6.00 ​ Investor ​ 10,227 ​ ​ ​ ​ 0.61 June 2019 public offering ​ ​ $ 7.50 ​ Placement agent ​ 54,910 ​ ​ ​ ​ 1.46 Outstanding as of December 31, 2022 ​ ​ ​ ​ ​ 1,065,137 ​ ​ $ 15.94 3.80 ​ In connection with the December 2021 registered direct offering, the Company issued investor warrants to purchase an aggregate of 1.0 million shares of common stock at an exercise price of $16.50 with a term of five years and are immediately exercisable (see Note 9 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assumptions for warrants issued December 15, 2021: December 31, 2022 December 31, 2021 ​ ​ ​ ​ Exercise Price ​ ​ $ 16.50 ​ ​ $ 16.50 ​ Volatility ​ 121 % 101 % Equivalent term (years) ​ 3.96 ​ 4.96 ​ Risk-free interest rate ​ 4.11 % 1.25 % Number of warrants ​ 1,000,000 ​ 1,000,000 ​ Derivative liability ​ ​ $ 44,000 ​ ​ $ 5,597,000 ​ ​ In connection with the August 2018 confidentially marketed public offering, the Company issued investor warrants to purchase an aggregate of 1.3 million shares of common stock at an exercise price of $6.00 with a term of five years . Due to certain derivative features, these warrants were accounted for under liability accounting and are recorded at fair value each reporting period. As of December 31, 2022 and 2021, these warrants had a fair value of approximately $0 and $52,000 , respectively. The assumptions, using the Black-Scholes valuation model, as of December 31, 2022, December 31, 2021, and at issuance were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Assumptions for warrants issued August 13, 2018: December 31, 2022 December 31, 2021 ​ ​ ​ ​ Exercise Price ​ ​ $ 6.00 ​ ​ $ 6.00 ​ Volatility ​ 200 % 107 % Equivalent term (years) ​ 0.61 ​ 1.61 ​ Risk-free interest rate ​ 4.75 % 0.60 % Number of warrants ​ 10,227 ​ 10,227 ​ Derivative liability ​ ​ $ - ​ ​ $ 52,000 ​ ​ In connection with the June 2017 registered direct offering, the Company issued investor warrants to purchase an aggregate of 733,334 shares of common stock at an exercise price of $11.40 with a term of five years . Due to certain derivative features, these warrants are accounted for under liability accounting and are recorded at fair value each reporting period. The investor warrants expired on June 1, 2022. As of December 31, 2021, these warrants had a fair value of ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assumptions for warrants issued June 2, 2017: December 31, 2021 ​ ​ ​ ​ Exercise Price ​ ​ $ 11.40 ​ ​ ​ ​ Volatility ​ 92 % ​ ​ ​ Equivalent term (years) ​ 0.42 ​ ​ ​ ​ Risk-free interest rate ​ 0.15 % ​ ​ ​ Number of warrants ​ 135,128 ​ ​ ​ ​ Derivative liability ​ ​ $ 156,000 ​ ​ ​ ​ ​ There were no issuances or exercises of warrants during the year ended December 31, 2022. The total value for the warrant derivative liability as of December 31, 2022 was approximately $44,000 (see Note 8 During the year ended December 31, 2021, the Company issued 18,940 shares of its common stock as a result of the exercise of investor warrants with an exercise price of $6.00. The Company received proceeds of $114,000 during the period related to these investor warrant exercises. In addition, former placement agents elected to exercise 35,249 of their warrants utilizing the net exercise option, where the total number of shares of common stock issued was reduced to cover the exercise price and, as such, the Company issued 20,275 shares of common stock. The Company did not receive any cash related to the exercise of placement agent warrants.

Fair Value Considerations

Fair Value Considerations	12 Months Ended
	Dec. 31, 2022
Fair Value Considerations
Fair Value Considerations	Note 8 – Fair Value Considerations Authoritative guidance defines fair value as the price that would be received upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources not affiliated with the Company. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows: Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to the Company for identical assets or liabilities; Level 2: Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Level 3: Unobservable inputs that are supported by little or no market activity. ​ The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses, and warrant derivative liability. Warrants are recorded at estimated fair value utilizing the Black-Scholes warrant pricing model. ​ The Company’s assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. The Company’s policy is to recognize transfers in and/or out of the fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. The Company has consistently applied the valuation techniques in all periods presented. The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2022 and 2021, by level within the fair value hierarchy: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements Using ​ Level 1 Level 2 Level 3 Total December 31, 2022 ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ Warrant derivative liability ​ $ — ​ $ — ​ $ 44,000 ​ $ 44,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ Warrant derivative liability ​ $ — ​ $ — ​ $ 5,805,000 ​ $ 5,805,000 ​ The recurring warrant derivative liability was valued using the Black-Scholes valuation methodology because that model embodies all the relevant assumptions that address the features underlying these instruments. The significant assumptions in valuing the warrant derivative liability as of December 31, 2022, December 31, 2021, and at issuance are disclosed in Note 7 ​ The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy: ​ ​ ​ ​ ​ Derivative Instruments ​ ​ ​ ​ Balance as of December 31, 2021 ​ $ 5,805,000 Change in fair value ​ ​ (5,761,000) Balance as of December 31, 2022 ​ $ 44,000 ​

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2022
Common Stock.
Common stock	N Authorized Shares The Company had 300.0 million authorized shares of common stock as of December 31, 2022 and 2021. The following table summarizes the Company’s remaining authorized shares available for future issuance: ​ ​ ​ ​ ​ December 31, 2022 ​ ​ ​ Authorized shares ​ 300,000,000 ​ ​ ​ Common stock outstanding ​ 15,102,877 Options outstanding ​ 297,460 Warrants outstanding ​ 1,065,137 Reserved for issuance under 2019 Stock and Incentive Plan ​ 441,300 Available shares for future issuance ​ 283,093,226 ​ Registered Direct Offering ​ In December 2021, the Company completed a registered direct offering whereby it issued 1.67 million shares of its common stock at a price of $13.50 per share, along with investor warrants to purchase up to 1.0 million shares of common stock, generating gross proceeds of $22.5 million. In connection with this offering, the Company entered into a Placement Agent Agreement with the placement agent. Pursuant to the Placement Agent Agreement, the placement agent received a 7% commission of $1.6 million, and $75,000 as compensation for other costs related to the offering. The Company also incurred expenses related to legal, accounting, and other registration costs of $167,000 . The shares and warrants were offered and sold pursuant to the Company’s shelf registration statement. ​ The investor warrants issued in connection with the registered direct offering have an exercise price of $16.50 per share and are immediately exercisable with a term of five years from issuance. Based on the terms of the warrant and related securities law, the contract does not meet the criteria within Accounting Standards Codification (“ASC”) 815 “ Derivatives and Hedging ” to permit the company to settle in unregistered shares. Therefore, the Company could be forced to cash settle the warrants. Based on this derivative feature, these warrants must be accounted for as a liability at fair value under ASC 815. On the date of issuance, these warrants were valued at $6.7 million, using the Black-Scholes valuation model (see Note 7 ) and represents a reduction in additional paid-in capital at the time of issuance. ​ ATM Equity Offering Program Sales Agreement In February 2020, the Company entered into a Sales Agreement with two agents to implement an “at the market” (ATM) equity offering program under which the Company, from time to time and at its sole discretion, may offer and sell shares of its common stock having an aggregate offering price up to $50.0 million to the public through the agents until (i) each agent declines to accept the terms for any reason, (ii) the entire amount of shares has been sold, or (iii) the Company suspends or terminates the Sales Agreement. The Sales Agreement includes customary indemnification rights in favor of the agents and provides that the agents will be entitled to an aggregate fixed commission of 4.0% of the gross proceeds (2.0% to each agent) to the Company from any shares sold pursuant to the Sales Agreement. Due to its terms and conditions, the Company does not anticipate any sales of stock under the Sales Agreement. During the year ended December 31, 2022, the Company had no activity under the ATM equity offering program. During December 31, 2021, the Company sold 416,406 shares of common stock which resulted in net proceeds of $10.0 million after deducting $0.5 million for placement agent commissions and issuance costs. Issuance of Common Stock for Services The Company issued 3,604 shares of common stock under the Ampio Pharmaceuticals, Inc. 2019 Stock and Incentive Plan (the “2019 Plan”), valued at $80,000, as partial compensation for the services of non-employee directors, during the year ended December 31, 2021. During the year ended December 31, 2022, the Company did not issue any shares of common stock as partial compensation for the services of non-employee directors.

Equity Instruments

Equity Instruments	12 Months Ended
	Dec. 31, 2022
Equity
Equity	Note 10 – Equity Instruments In December 2019, the Company’s Board of Directors and stockholders approved the adoption of the 2019 Plan, under which shares were reserved for future issuance of equity related awards classified as option awards/grants, restricted stock awards and other equity related awards. The 2019 Plan permits grants of equity awards to employees, directors and consultants. The stockholders approved a total of 10.0 million shares to be reserved for issuance under the 2019 Plan, which was reduced to 666,667 shares as a result of the 15-to-1 reverse stock split effective November 9, 2022. The Company’s previous 2010 Stock and Incentive Plan (the “2010 Plan”) was cancelled concurrently with the adoption of the 2019 Plan. The following table summarizes the activity of the 2019 Plan and the shares available for future equity awards as of December 31, 2022: ​ ​ ​ ​ ​ 2019 Plan ​ ​ ​ ​ Total shares reserved for equity awards as of December 31, 2021 ​ ​ 294,489 Options granted ​ (106,555) Forfeited, expired and/or cancelled equity option awards ​ ​ 184,132 Forfeited, expired and/or cancelled equity restricted stock awards ​ ​ 60,000 Shares forfeited to settle exercise price and tax obligation ​ ​ 9,234 Remaining shares available for future equity awards as of December 31, 2022 ​ ​ 441,300 ​ Options The Company’s stock option activity is summarized in the table below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Weighted Average ​ ​ ​ ​ Number of ​ Average ​ Remaining ​ ​ Aggregate ​ ​ Options ​ Exercise Price ​ Contractual Life ​ ​ Intrinsic Value Outstanding as of December 31, 2021 500,466 ​ $ 16.81 7.36 $ — Granted 106,555 ​ $ 7.14 ​ ​ ​ Forfeited, expired and/or cancelled ​ (309,561) ​ $ 15.26 ​ ​ ​ ​ ​ Outstanding as of December 31, 2022 297,460 ​ $ 14.97 ​ 6.41 ​ $ — Exercisable as of December 31, 2022 257,216 ​ $ 15.85 6.59 $ — ​ Outstanding options that were issued in accordance with the 2010 Plan and 2019 Plan are summarized in the table below: ​ ​ ​ ​ ​ Outstanding Options by Plan ​ December 31, 2022 2010 Plan ​ ​ 116,571 2019 Plan ​ ​ 180,889 Outstanding as of December 31, 2022 ​ ​ 297,460 ​ Stock options outstanding at December 31, 2022 are summarized in the table below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Weighted Weighted Average ​ ​ Options ​ Average ​ Remaining Range of Exercise Prices ​ Outstanding ​ Exercise Price ​ Contractual Lives Up to $7.50 63,457 ​ $ 6.67 3.73 $7.51 - $15.00 140,327 ​ $ 10.39 6.45 $15.01 - $22.50 ​ 53,600 ​ $ 17.30 ​ 8.83 $22.51 and above 40,076 ​ $ 40.98 7.31 Total 297,460 ​ $ 14.97 6.41 ​ Restricted Stock Awards In connection with the three executive employment agreements issued in October 2021, the Company awarded 119,000 shares of restricted stock in accordance with the 2019 Plan, of which a portion vested immediately, with the remaining shares of restricted stock awards vesting annually on January 1st until 2025. The 2019 Plan allows the restricted stock award grantee to authorize the Company to withhold shares of common stock to settle the tax obligation at such time the shares vest. The shares of restricted stock that vested immediately were subject to statutory tax withholdings and all three employees authorized the Company to withhold shares of common stock to settle the tax obligation, which resulted in a forfeiture of 9,234 shares of common stock, due to the termination of two executives during 2022, and 15,233 net shares of common stock being issued during the year ended December 31, 2022. The restricted stock awards activity for the twelve-month period ended December 31, 2022 is summarized in the table below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ Average Grant-Date ​ ​ Aggregate ​ ​ Awards ​ Fair Value ​ ​ Intrinsic Value Nonvested as of December 31, 2021 97,867 ​ $ 24.60 ​ ​ Vested (24,467) ​ $ 24.60 $ — Forfeited ​ (60,000) ​ ​ ​ ​ ​ ​ Nonvested as of December 31, 2022 13,400 ​ $ 24.60 ​ ​ ​ ​ Share-based Compensation ​ The Company computes the fair value for all options granted or modified using the Black-Scholes option pricing model. To calculate the fair value of the options, certain assumptions are made regarding components of the model, including the fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to the valuation. The Company calculates its volatility assumption using the actual changes in the market value of its stock. Forfeitures are recognized as they occur. The Company’s historical option exercises do not provide a reasonable basis to estimate an expected term due to the lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method. The simplified method calculates the expected term as the average of the vesting term plus the contractual life of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. The Company computed the fair value of options granted and modified during the period ended December 31, 2022 and December 31, 2021, using the following assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 ​ ​ ​ ​ ​ ​ ​ Expected volatility 116.83% - 119.43 % ​ 113% - 127 % Risk free interest rate 1.26% - 1.94 % ​ 0.78% - 1.38 % Expected term (years) 5.45 - 6.51 ​ 5.00 - 6.50 ​ ​ Based on these assumptions, the Company recognized approximately $1.1 million of share-based compensation related to options, which was partially offset by $0.2 million due to reversals for non-vested shares for director and employee forfeitures during the year ended December 31, 2022. ​ The Company also computes the fair value for all restricted stock awards based on the closing stock price on the grant date and recognizes share-based compensation ratably over the requisite service period which approximates the vesting period. The Company recognized $0.5 million of share-based compensation relating to restricted stock awards which was fully offset by $0.5 million due to forfeitures. ​ Share-based compensation expense related to the fair value of stock options and restricted stock awards is included in the statements of operations as research and development expenses and general and administrative expenses as set forth in the table below. The Company determined the fair value as of the date of grant for options using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period. The following table summarizes stock-based compensation for the years ended December 31, 2022 and December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 Research and development expenses ​ ​ Share-based compensation, net of forfeitures ​ $ 139,000 ​ $ 46,000 ​ ​ ​ ​ ​ ​ ​ General and administrative expenses ​ ​ Issuance of common stock for services (see Note 9 ​ — ​ 80,000 Share-based compensation, net of forfeitures ​ 814,000 ​ 2,678,000 ​ ​ ​ ​ ​ ​ ​ Total share-based compensation, net of forfeitures ​ $ 953,000 ​ $ 2,804,000 ​ ​ ​ ​ ​ ​ ​ Unrecognized share-based compensation expense related to stock options as of December 31, 2022 ​ $ 185,000 ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining years to vest for stock options ​ ​ 1.42 ​ ​ ​ ​ ​ ​ ​ ​ Unrecognized share-based compensation expense related to restricted stock awards as of December 31, 2022 ​ $ 116,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining years to vest for restricted stock awards ​ ​ 2.01 ​ ​ ​ ​

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Taxes
Income Taxes	Note 11 – Income Taxes Income tax expense (benefit) resulting from applying statutory rates in jurisdictions in which the Company is taxed (Federal and State of Colorado) differs from the income tax provision (benefit) in the Company’s financial statements. The following table reflects the reconciliation for the respective periods: ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, ​ ​ 2022 2021 Benefit at federal statutory rate (21.0) % (21.0) % State, net of federal income tax impact (4.0) % (4.4) % Stock-based compensation 4.0 % 0.1 % Registered offering gain/warrant expense (7.2) % (4.6) % Change in state deferred tax rate ​ 1.5 % 0.0 % Expiration of tax attribute carryforwards ​ 0.6 % 1.1 % Other ​ 0.0 % 2.1 % Change in valuation allowance 26.1 % 26.7 % Effective tax rate 0.0 % 0.0 % ​ Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial reporting purposes. The approximate tax effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective periods: ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, ​ 2022 2021 Long-term deferred income tax assets (liabilities): ​ ​ Accrued liabilities ​ $ 3,000 ​ $ 96,000 Interest expense carryforward ​ ​ — ​ ​ 73,000 ROU asset ​ (18,000) ​ (155,000) Lease liability ​ ​ 150,000 ​ ​ 228,000 Net operating loss carryforward ​ 50,196,000 ​ 47,858,000 Share-based compensation ​ 459,000 ​ 1,050,000 Unrealized loss on trading security ​ 768,000 ​ 772,000 Property and equipment ​ 606,000 ​ 113,000 Warrants ​ 65,000 ​ 96,000 Capitalized development costs ​ ​ 2,093,000 ​ ​ — Asset retirement obligation ​ ​ 68,000 ​ ​ — Other ​ ​ 1,000 ​ ​ 1,000 Less: Valuation allowance ​ (54,391,000) ​ (50,132,000) Total long-term deferred income tax assets (liabilities) ​ $ — ​ $ — ​ As of December 31, 2022, Ampio has approximately $205.0 million in net operating loss (“NOL”) carryforwards that, subject to limitation, may be available in future tax years to offset taxable income. These net operating loss carryforwards expire from 2023 through 2037. Approximately $74.5 million of the NOL carryforward carries forward indefinitely. Under the provisions of the Internal Revenue Code, substantial changes in the Company’s ownership may result in limitations on the amount of NOL carryforwards that can be utilized in future years. ​ The Company has provided a full valuation allowance against its deferred tax assets as it has determined that it is not more likely than not that recognition of such deferred tax assets will be utilized in the foreseeable future. The amount of income taxes and related income tax positions taken are subject to audits by federal and state tax authorities. The Company has adopted accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon recognition of the benefit. The Company believes that it has no material uncertain tax positions and has fully reserved against its future tax benefit with a valuation allowance and does not expect significant changes in the amount of unrecognized tax benefits to occur within the next twelve months. The Company’s policy is to record a liability for the difference between benefits that are both recognized and measured pursuant to GAAP and tax positions taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The Company reports tax-related interest and penalties as a component of income tax expense. During the periods reported, management of the Company has concluded that no significant tax position requires recognition. The Company files income tax returns in the United States federal and various state jurisdictions. The Company is no longer subject to income tax examinations for federal income taxes before 2019 or for Colorado before 2018. Net operating loss carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance is limited to the NOL utilized. Accordingly, the Company may be subject to examination for prior NOL’s generated as such NOL’s are utilized.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share
Earnings Per Share	Note 12 – Earnings Per Share Basic earnings per share is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is based on the treasury stock method and computed by dividing net loss available to common stockholders by the diluted weighted-average shares of common stock outstanding during each period. The Company’s potentially dilutive shares include stock options, warrants for the shares of common stock and restricted stock awards. The potentially dilutive shares are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when the effect is dilutive. The investor warrants are treated as equity in the calculation of diluted earnings per share in both the computation of the numerator and denominator, if dilutive. The following table sets forth the calculations of basic and diluted earnings per share for the year ended December 31, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 Net loss ​ $ (16,337,000) ​ $ (17,075,000) Less: decrease in fair value of investor warrants ​ ​ (5,761,000) ​ ​ (3,492,000) Net loss available to common stockholders ​ $ (22,098,000) ​ $ (20,567,000) ​ ​ ​ ​ ​ ​ ​ Basic weighted-average common shares outstanding ​ ​ 15,072,308 ​ ​ 13,286,605 Add: dilutive effect of equity instruments ​ ​ — ​ ​ 377,597 Diluted weighted-average shares outstanding ​ ​ 15,072,308 ​ ​ 13,664,202 Earnings per share – basic ​ $ (1.08) ​ $ (1.29) Earnings per share – diluted ​ $ (1.47) ​ $ (1.51) ​ The potentially dilutive shares of common stock equivalents that have been excluded from the calculation of net loss per share because of the anti-dilutive effect as of December 31, 2022 and 2021 are as follows: ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 Warrants to purchase shares of common stock 1,065,137 ​ 842,597 Outstanding stock options 297,460 ​ 500,466 Restricted stock awards 13,400 ​ 97,867 Total potentially dilutive shares of common stock 1,375,997 ​ 1,440,930 ​

Litigation

Litigation	12 Months Ended
	Dec. 31, 2022
Litigation.
Litigation	Note 13 – Litigation From time to time, the Company may be a party to litigation arising in the ordinary course of business. In addition, as Kain v. Ampio Pharmaceuticals, Inc., et al., 22-cv-2105 On August 17, 2022, a putative Ampio shareholder filed a securities fraud class action against the Company, its current CEO Michael A. Martino and two former executives, Michael Macaluso and Holli Cherevka, in the United States District Court for the District of Colorado, captioned Kain v. Ampio Pharmaceuticals, Inc., et al. The Complaint relies largely on Ampio’s announcement on May 16, 2022, that it had formed a special Board committee to investigate the statistical analysis of Ampio’s AP-013 clinical trial and the unauthorized provision of Ampion to various individuals who were not participating in clinical trials, and Ampio’s further announcement on August 3, 2022, that the investigation had revealed that various employees were aware that the AP-013 trial did not demonstrate efficacy for Ampion’s primary endpoints and did not fully and timely report the results of the trial and the timing of unblinding data from the trial. Based on the Company’s reports, the Complaint asserts that various statements made by the Company during the Class Period were false and misleading because they: (i) inflated Ampio’s ability to successfully obtain FDA approval for Ampion; (ii) inflated the results of the AP-013 clinical trial and failed to disclose the timing of unblinding the data from the study; and (iii) overstated the Company’s business, operations and prospects. The Complaint seeks an unspecified amount of compensatory damages as well as attorneys’ fees and costs. On October 17, 2022, six putative shareholders filed motions seeking to be named lead plaintiff. On November 7, 2022, of the movants filed oppositions to each other’s motions; the remaining movants either withdrew their motions or filed non-oppositions to another putative shareholder’s motion. The Court has not yet ruled on the competing motions for appointment of lead plaintiff. In the interim, the Court approved the parties’ joint motion to stay proceedings, and all deadlines are deferred until after a decision on the lead plaintiff motion(s). Ampio intends to defend itself vigorously against this action. Maresca v. Martino, et al., 22-cv-2646-KLM On October 7, 2022, putative Ampio shareholder Robert Maresca filed a Verified Shareholder Derivative Complaint in the United States District Court for the District of Colorado, captioned Maresca v. Martino, et al. , 22-cv-2646-KLM. The derivative complaint, brought on behalf of the Company, asserts claims against a number of current and former executives and directors of the Company, namely Michael A. Martino, Michael Macaluso, Holli Cherevka, David Bar-Or, David Stevens, J. Kevin Buchi, Philip H. Coelho and Richard B. Giles. Based largely on the same allegations as the Kain securities fraud class action complaint (including Ampio’s reports in May and August, 2022, regarding its internal investigation and findings), the Complaint asserts that the individual defendants caused the Company to make false or misleading statements in its SEC filings by “hyp[ing Ampio’s] ability to successfully file a BLA for Ampion;” “exaggerate[ing] results of the AP-013 study;” “misstat[ing] the true timing of unblinding of data from the AP-013 study;” and “fail[ing] to maintain internal controls.” The Complaint also asserts that the defendants failed to exercise due care and comply with the Company’s policies and procedures designed to ensure Board and Audit Committee oversight of the business operations and that ethical business practices were maintained. It also contends that of the defendants (Cherevka and Coelho) sold Company stock while in possession of material non-public information at artificially inflated prices in violation of the Company’s insider trading restrictions. The Complaint asserts that the individuals should not have received compensation while violating their duties to the Company. The Complaint also alleges that the defendants caused the Company to repurchase its own stock at artificially inflated prices, causing damage to the Company itself. The Complaint asserts six causes of action on behalf of the Company and against the individual defendants: (1) violations of Section 14(a) of the Exchange Act based on purportedly false and misleading statements in the Company’s proxy statements; (2) violations of Section 10(b) of the Exchange Act and Rule 10b-5 promulgated thereunder; (3) control person liability under Section 20(a) of the Exchange Act; (4) breach of fiduciary duty; (5) unjust enrichment; and (6) waste of corporate assets. The Complaint seeks an unspecified amount of compensatory and restitution damages to be paid to Ampio, together with pre- and post-judgment interest, as well as injunctive relief imposing certain corporate governance reforms and attorneys’ fees and costs. On November 2, 2022, the Company and plaintiff (together with plaintiff in a second derivative action -- the Marquis plaintiffs as co-lead counsel. That same day, the Company and plaintiff filed a stipulation providing the Company additional time to answer, move or otherwise respond to the Complaint. On January 10, 2023, after the Company received additional extensions of time to respond, the Court granted consolidation of the Maresca Marquis actions but denied appointment of co-lead counsel for plaintiffs without prejudice. On January 11, 2023, Plaintiffs renewed their motion for appointment of co-lead counsel. On January 12, 2023, the Court granted the renewed motion and appointed co-lead counsel for plaintiffs. On January 17, 2023, the parties filed a joint stipulated motion seeking a temporary stay of the consolidated derivative actions, subject to various conditions, until the earlier of: (1) the dismissal of the Kain Kain action; or (3) another derivative action being filed that is not stayed for the same duration. On January 25, 2023, the Court granted the motion for temporary stay. Accordingly, all deadlines are deferred until the stay is terminated. Ampio intends to defend itself vigorously against this action. Marquis v. Martino, et al., 22-cv-2803-KLM On October 25, 2022, putative shareholder Samantha Marquis filed a derivative complaint in the United States District Court for the District of Colorado, captioned Marquis v. Martino, et al., 22-cv-2803-KLM. The Complaint, filed on behalf of Ampio, asserts that various current and former officers and directors of Ampio – namely, Michael Martino, Michael Macaluso, Holli Cherevka, David Bar-Or, David Stevens, Kevin Buchi, Philip Coelho, and Richard Giles, breached their fiduciary duties as directors and/or officers and violated Section 14(a) of the Exchange Act by causing the Company to file false and misleading proxy statements. The Complaint focuses on the Company’s alleged failure to timely report that the results of the AP-013 trial for Ampion were unfavorable, failing to show efficacy on the co-primary endpoints of pain and function, and the Company’s alleged failure to disclose the results of and timing of unblinding the study data. The Complaint asserts that the individual defendants breached their fiduciary duties by making or causing the Company to make materially false and misleading statements regarding Ampio’s business, operations and prospects and by failing to maintain adequate internal controls. Based on these allegations, the Complaint asserts causes of action on behalf of the Company: (1) violations of Section 14(a) of the Exchange Act against all defendants other than Cherevka; and (2) breach of fiduciary duty against all defendants. Based on these claims, the Complaint seeks judgment in favor of the Company and against the individual defendants in an unspecified amount of compensatory and restitution damages, together with pre- and post-judgment interest and costs of the action including reasonable attorneys’ and experts’ fees as well as a mandatory injunction requiring Ampio and the defendants to reform and improve the corporate governance and internal controls of the Company. On November 2, 2022, the Company and plaintiff (together with plaintiff in the previously filed Maresca On January 10, 2023, the Court granted consolidation of the Maresca Marquis actions but denied appointment of co-lead counsel for plaintiffs without prejudice. On January 11, 2023, Plaintiffs renewed their motion for appointment of co-lead counsel. On January 12, 2023, the Court granted the renewed motion and appointed co-lead counsel for plaintiffs. On January 17, 2023, the parties filed a joint stipulated motion seeking a temporary stay of the consolidated derivative actions, subject to various conditions, until the earlier of: (1) the dismissal of the Kain Kain action; or (3) another derivative action being filed that is not stayed for the same duration. On January 25, 2023, the Court granted the motion for temporary stay. Accordingly, all deadlines are deferred until the stay is terminated. Ampio intends to defend itself vigorously against this action. McCann v. Martino, et al On January 27, 2023, putative shareholder John McCann filed a derivative complaint in the District Court, City & County of Denver, State of Colorado, captioned McCann v. Martino et al ., 2023cv30287. The Complaint, filed on behalf of Ampio, asserts that various current and former officers and directors of Ampio – namely, Michael Martino, J. Kevin Buchi, David Stevens, Elizabeth Jobes, Holli Cherevka, David Bar-Or, Philip H. Coelho, and Richard B. Giles, breached their fiduciary duties as directors and/or officers by allowing the Company to issue false and misleading statements, The Complaint focuses on the Company’s alleged failure to timely report that the results of the AP-013 trial for Ampion were unfavorable, failing to show efficacy on the co-primary endpoints of pain and function, and the Company’s alleged failure to disclose the results of and timing of unblinding the study data. The Complaint asserts that the individual defendants breached their fiduciary duties by allowing the Company to make materially false and misleading statements regarding Ampio’s business, operations and prospects and by failing to maintain adequate internal controls. Based on these allegations, the Complaint asserts five causes of action on behalf of the Company: (1) breach of fiduciary duty against the current directors; (2) gross mismanagement against the current directors; (3) waste of corporate assets against the current directors; (4) unjust enrichment against all defendants; and (5) breach of fiduciary duty by insider trading against defendants Cherevka and Coelho. Based on these claims, the Complaint seeks judgment in favor of the Company and against the individual defendants in an unspecified amount of compensatory damages, costs of the action including reasonable attorneys’ and experts’ fees as well as a mandatory injunction requiring Ampio to reform and improve the corporate governance and internal procedures of the Company. Defendant Cherevka was served and by order dated February 9, 2023, obtained an extension of time to respond to the Complaint through March 31, 2023. On March 2, 2023, the parties filed a joint stipulated motion seeking a temporary stay of the action, subject to various conditions, until the earlier of: (1) the dismissal of the Kain Kain action; or (3) another derivative action being filed that is not stayed for the same duration. On March 3, 2023, the Court granted the motion for temporary stay. Accordingly, all deadlines are deferred until the stay is terminated. Ampio intends to defend itself vigorously against this action. SEC Investigation On October 12, 2022, the Securities and Exchange Commission, or SEC, entered an order directing private investigation and designating officers to take testimony to determine whether we or any other entities or persons have engaged in, or are about to engage in, any violations of the securities laws. The SEC has since issued subpoenas to the Company and numerous current and former officers, directors, employees and consultants of the Company. We intend to cooperate fully with the SEC.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2022
Employee Benefit Plan
Employee Benefit Plan	Note 14 – Employee Benefit Plan The Company has a 401(k) plan that allows participants to contribute a portion of their salary, subject to eligibility requirements and annual IRS limits. The Company provided $67,000 matching employee contributions during the year ended December 31, 2022.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events
Subsequent Events	Note 15 – Subsequent Event Ampio Pharmaceuticals, Inc. (the “Company”) is a party to a Lease Agreement (the “Lease”) with Beta Investors Group, LLC (successor by assignment to NCWP – Inverness Business Park, LLC) (the “Landlord”) dated December 13, 2013 pursuant to which the Company has leased office and manufacturing space in Suite 200 and Suite 204 in the building located at 373 Inverness Parkway, Englewood, Colorado (the “Premises”). Effective March 1, 2023, the Company entered into a sublease agreement with the consent of the Landlord pursuant to which the Company will sublease the Premises for a term commencing on March 1, 2023 and continuing until the expiration of the Lease on September 30, 2024. However, the address of the Company’s principal executive offices continues to be 373 Inverness Parkway, Suite 200, Englewood, Colorado 80112. ​

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and related disclosures in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions primarily include the Company’s projected current and long-term liquidity, the clinical trial accrual, projected useful lives and potential impairment of long-lived assets and ROU asset (“right-of-use asset”). The Company develops these estimates using its judgment based upon the facts and circumstances known at the time.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers instruments purchased with an original maturity of three months or less to be cash equivalents. The Company’s investment policy is to preserve principal and maintain liquidity. On March 10, 2023, the Federal Deposit Insurance Corporation (“FDIC”) placed Silicon Valley Bank (SVB) into receivership. At that time, the Company held approximately in a deposit account at SVB. The balance of the Company’s cash was held in an investment account that is not a deposit account and therefore, these amounts would not be impacted by the FDIC’s receivership of SVB or subject to FDIC insurance limits. Following the joint statement by the U.S. Treasury, Federal Reserve and the FDIC on March 12, 2023, the Company regained access to all of its deposit account funds. The Company refined its cash management strategy in order to further mitigate the potential risk of loss associated with deposit accounts balances in excess of the FDIC insured amount.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts or foreign currency hedging arrangements. The Company consistently maintains its cash and cash equivalent balances in the form of bank demand deposits, United States federal government backed treasury securities and liquid money market fund accounts with financial institutions that management believes are creditworthy. The Company periodically monitors its cash positions with, and the credit quality of, the financial institutions with which it invests. During the years ended December 31, 2022 and 2021, the Company has maintained balances in excess of federally insured limits.
Fixed Assets	Fixed Assets Fixed assets are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals and the related cost required to get certain equipment in operating condition. The Company charges routine and ongoing maintenance and repairs to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of property and equipment is depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the remaining life of the lease.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company performs an evaluation on an annual basis, or sooner if management believes a triggering event has occurred, of the recoverability related to the carrying value of its long-lived assets to determine if facts and circumstances indicate that the carrying value of assets may be impaired and if any adjustment is warranted. The Company recorded impairment charges of $1.6 million and $0.3 million on its long-lived and ROU assets, respectively, during the year ended December 31, 2022. No impairment existed for long-lived or ROU assets
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses, and warrant derivative liability. The carrying amounts of cash and cash equivalents, accounts payable and accrued expenses are carried at cost, which approximates fair value due to the short maturity of these instruments. The warrant derivative liability is recorded at estimated fair value based on utilization of the Black-Scholes warrant pricing model depending on facts and circumstances. See Note 7 and Note 8
Share-Based Compensation	Share-Based Compensation The Company accounts for share-based payments by recognizing compensation expense based upon the estimated fair value of the share-based payments on the date of grant. The Company determines the estimated fair value of the share-based payments granted using the fair market value or Black-Scholes option pricing model and recognizes compensation costs ratably over the requisite service period which approximates the vesting period using the graded method. See Note 10
Income Taxes	Income Taxes Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a valuation allowance against all of its net deferred tax assets, as management has concluded that it is more likely than not that the net deferred tax asset will not be realized through projected future taxable income, based primarily on the Company’s ongoing history of operating losses and the lack of taxable income in the foreseeable future. See Note 11
Research and Development	Research and Development Research and development costs are expensed as incurred in the respective periods.
Liquidity	Liquidity The company recognized a net loss of $16.3 million, which is primarily attributable to operating expenses of $22.3 million, partially offset by the non-cash derivative gain of $5.8 million (see Note 8 Over this period, we have continued to be focused on research and pre-clinical / clinical drug development all of which has required raising a substantial amount of capital. ​ Recently, we announced that we completed clinical trial reports for all legacy Ampion trials and submitted those reports to the appropriate agencies for review and ultimate publication on Clinical Trials.gov. In addition, we also informed the FDA that we have discontinued further development of the product and withdrawn the INDs. The combination of these activities concludes the development efforts on Ampion. ​ In addition, we have continued to focus on reducing operating costs, including but not limited to, the reduction of personnel expense to correspond to the conclusion of development efforts relating to Ampion and have engaged a nationally recognized commercial real estate broker to assist with sublease of the existing office space. As previously stated, we are currently conducting preclinical studies to evaluate the safety and efficacy of AR-300 with the initial target for treatment of OAK. ​
Adoption of Recent Accounting Pronouncements	Adoption of Recent Accounting Pronouncements The Company has not adopted any recent accounting pronouncements during the year ended December 31, 2022, as none were deemed to be applicable. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standard Board (the “FASB”) issued ASU 2020-06, “ Debt (Subtopic 470-20); Debt with Conversion and Other Options and Derivatives and Hedging (Subtopic 815-40) Contracts in Entity’s Own Equity This Annual Report on Form 10-K does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Prepaid Expenses and Other (Tab

Prepaid Expenses and Other (Tables)	12 Months Ended
	Dec. 31, 2022
Prepaid Expenses and Other
Schedule Of Prepaid Expenses and other balances	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 ​ December 31, 2021 ​ ​ ​ ​ ​ ​ ​ Unamortized commercial insurance premiums ​ $ 610,000 ​ $ 465,000 Deposits ​ ​ 34,000 ​ ​ 884,000 Professional fees ​ ​ 19,000 ​ ​ 235,000 Clinical trial inventory ​ ​ — ​ ​ 72,000 Other ​ ​ 13,000 ​ ​ 84,000 Total prepaid expenses and other ​ $ 676,000 ​ $ 1,740,000

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Fixed Assets
Schedule of Fixed Assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Estimated ​ ​ ​ ​ ​ ​ ​ ​ Useful Lives ​ ​ ​ (in Years) December 31, 2022 ​ December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Leasehold improvements 10 ​ $ 4,965,000 ​ $ 6,075,000 Manufacturing facility/clean room 3 - 8 ​ 2,803,000 ​ 2,984,000 Lab equipment and office furniture 5 - 8 ​ 1,661,000 ​ 1,739,000 Fixed assets, gross ​ ​ ​ ​ 9,429,000 ​ ​ 10,798,000 Accumulated depreciation ​ ​ ​ ​ (9,245,000) ​ ​ (8,234,000) Fixed assets, net ​ ​ ​ $ 184,000 ​ $ 2,564,000 ​
Schedule Of Depreciation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 2021 ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization expense ​ $ 1,048,000 ​ $ 1,094,000 ​

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Accounts Payable and Accrued Expenses
Schedule of accounts payable and accrued expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 ​ December 31, 2021 ​ ​ ​ ​ ​ Accounts payable ​ $ 97,000 ​ $ 427,000 Clinical trials ​ ​ 89,000 ​ ​ 2,995,000 Professional fees ​ 157,000 ​ 510,000 Commercial insurance premium financing ​ 189,000 ​ 269,000 Accrued severance ​ ​ 143,000 ​ ​ — Accrued compensation ​ ​ — ​ ​ 389,000 Other ​ ​ 177,000 ​ ​ 221,000 Accounts payable and accrued expenses ​ $ 852,000 ​ $ 4,811,000 ​

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Litigation.
Summary of reconciliation of the Company's undiscounted payments for its facility lease and the carrying amount of the lease liability	The following table provides a reconciliation of the Company’s remaining undiscounted payments for its facility lease and the carrying amount of the lease liability presented in the balance sheet as of December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Facility Lease Payments 2023 2024 2025 2026 2027 Thereafter ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Remaining Facility Lease Payments ​ $ 644,000 ​ $ 364,000 ​ $ 280,000 ​ $ — ​ $ — ​ $ — ​ $ — Less: Discount Adjustment ​ (30,000) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total lease liability ​ $ 614,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Lease liability-current portion ​ $ 340,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Long-term lease liability ​ $ 274,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Lease Expense	​ ​ ​ ​ ​ ​ ROU Asset ​ ​ ​ Balance as of December 31, 2021 ​ $ 629,000 Amortization ​ ​ (232,000) Impairment loss ​ ​ (322,000) Balance as of December 31, 2022 ​ $ 75,000 ​ The Company recorded lease expense in the respective periods is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 2021 ​ ​ ​ ​ ​ ​ ​ ​ Lease expense ​ $ 311,000 ​ $ 275,000 ​

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Company's warrant activity	The following table summarizes the Company’s warrant activity: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Weighted Average ​ ​ Number of ​ Average ​ Remaining ​ ​ Warrants ​ Exercise Price ​ Contractual Life ​ ​ ​ ​ ​ ​ ​ ​ Outstanding as of December 31, 2021 ​ 1,220,194 ​ ​ $ 15.36 ​ 4.24 Warrants expired ​ (155,057) ​ ​ $ 11.40 ​ ​ Outstanding as of December 31, 2022 1,065,137 ​ ​ $ 15.94 3.80 ​
Schedule of stockholders equity note warrants or rights classified as equity and liability	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Weighted Average ​ ​ ​ ​ ​ ​ ​ Number of ​ Average ​ Remaining Date ​ Exercise Price ​ Type ​ Warrants ​ Exercise Price ​ Contractual Life ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 2021 registered direct offering ​ ​ $ 16.50 ​ Investor ​ 1,000,000 ​ ​ ​ ​ 3.96 August 2018 public offering ​ ​ $ 6.00 ​ Investor ​ 10,227 ​ ​ ​ ​ 0.61 June 2019 public offering ​ ​ $ 7.50 ​ Placement agent ​ 54,910 ​ ​ ​ ​ 1.46 Outstanding as of December 31, 2022 ​ ​ ​ ​ ​ 1,065,137 ​ ​ $ 15.94 3.80 ​
2017 public offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of assumptions for warrants issued	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assumptions for warrants issued June 2, 2017: December 31, 2021 ​ ​ ​ ​ Exercise Price ​ ​ $ 11.40 ​ ​ ​ ​ Volatility ​ 92 % ​ ​ ​ Equivalent term (years) ​ 0.42 ​ ​ ​ ​ Risk-free interest rate ​ 0.15 % ​ ​ ​ Number of warrants ​ 135,128 ​ ​ ​ ​ Derivative liability ​ ​ $ 156,000 ​ ​ ​ ​
2018 public offerings
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of assumptions for warrants issued	​ ​ ​ ​ ​ ​ ​ ​ ​ Assumptions for warrants issued August 13, 2018: December 31, 2022 December 31, 2021 ​ ​ ​ ​ Exercise Price ​ ​ $ 6.00 ​ ​ $ 6.00 ​ Volatility ​ 200 % 107 % Equivalent term (years) ​ 0.61 ​ 1.61 ​ Risk-free interest rate ​ 4.75 % 0.60 % Number of warrants ​ 10,227 ​ 10,227 ​ Derivative liability ​ ​ $ - ​ ​ $ 52,000 ​ ​
2021 public offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of assumptions for warrants issued	​ ​ ​ ​ ​ ​ ​ ​ ​ Assumptions for warrants issued December 15, 2021: December 31, 2022 December 31, 2021 ​ ​ ​ ​ Exercise Price ​ ​ $ 16.50 ​ ​ $ 16.50 ​ Volatility ​ 121 % 101 % Equivalent term (years) ​ 3.96 ​ 4.96 ​ Risk-free interest rate ​ 4.11 % 1.25 % Number of warrants ​ 1,000,000 ​ 1,000,000 ​ Derivative liability ​ ​ $ 44,000 ​ ​ $ 5,597,000 ​ ​

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Considerations
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2022 and 2021, by level within the fair value hierarchy: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements Using ​ Level 1 Level 2 Level 3 Total December 31, 2022 ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ Warrant derivative liability ​ $ — ​ $ — ​ $ 44,000 ​ $ 44,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ Warrant derivative liability ​ $ — ​ $ — ​ $ 5,805,000 ​ $ 5,805,000 ​
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy: ​ ​ ​ ​ ​ Derivative Instruments ​ ​ ​ ​ Balance as of December 31, 2021 ​ $ 5,805,000 Change in fair value ​ ​ (5,761,000) Balance as of December 31, 2022 ​ $ 44,000

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2022
Common Stock.
Schedule of remaining authorized Shares	​ ​ ​ ​ ​ December 31, 2022 ​ ​ ​ Authorized shares ​ 300,000,000 ​ ​ ​ Common stock outstanding ​ 15,102,877 Options outstanding ​ 297,460 Warrants outstanding ​ 1,065,137 Reserved for issuance under 2019 Stock and Incentive Plan ​ 441,300 Available shares for future issuance ​ 283,093,226 ​

Equity Instruments (Tables)

Equity Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Schedule of Stock Options Outstanding and Exercisable	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Weighted Weighted Average ​ ​ Options ​ Average ​ Remaining Range of Exercise Prices ​ Outstanding ​ Exercise Price ​ Contractual Lives Up to $7.50 63,457 ​ $ 6.67 3.73 $7.51 - $15.00 140,327 ​ $ 10.39 6.45 $15.01 - $22.50 ​ 53,600 ​ $ 17.30 ​ 8.83 $22.51 and above 40,076 ​ $ 40.98 7.31 Total 297,460 ​ $ 14.97 6.41 ​
Schedule of restricted stock awards activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ Average Grant-Date ​ ​ Aggregate ​ ​ Awards ​ Fair Value ​ ​ Intrinsic Value Nonvested as of December 31, 2021 97,867 ​ $ 24.60 ​ ​ Vested (24,467) ​ $ 24.60 $ — Forfeited ​ (60,000) ​ ​ ​ ​ ​ ​ Nonvested as of December 31, 2022 13,400 ​ $ 24.60 ​ ​ ​ ​
Schedule of Assumptions Used in Computing Fair Value of All Options Granted	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 ​ ​ ​ ​ ​ ​ ​ Expected volatility 116.83% - 119.43 % ​ 113% - 127 % Risk free interest rate 1.26% - 1.94 % ​ 0.78% - 1.38 % Expected term (years) 5.45 - 6.51 ​ 5.00 - 6.50 ​
Schedule of Stock-Based Compensation Expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 Research and development expenses ​ ​ Share-based compensation, net of forfeitures ​ $ 139,000 ​ $ 46,000 ​ ​ ​ ​ ​ ​ ​ General and administrative expenses ​ ​ Issuance of common stock for services (see Note 9 ​ — ​ 80,000 Share-based compensation, net of forfeitures ​ 814,000 ​ 2,678,000 ​ ​ ​ ​ ​ ​ ​ Total share-based compensation, net of forfeitures ​ $ 953,000 ​ $ 2,804,000 ​ ​ ​ ​ ​ ​ ​ Unrecognized share-based compensation expense related to stock options as of December 31, 2022 ​ $ 185,000 ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining years to vest for stock options ​ ​ 1.42 ​ ​ ​ ​ ​ ​ ​ ​ Unrecognized share-based compensation expense related to restricted stock awards as of December 31, 2022 ​ $ 116,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining years to vest for restricted stock awards ​ ​ 2.01 ​ ​ ​
Employee Stock Option
Schedule of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Weighted Average ​ ​ ​ ​ Number of ​ Average ​ Remaining ​ ​ Aggregate ​ ​ Options ​ Exercise Price ​ Contractual Life ​ ​ Intrinsic Value Outstanding as of December 31, 2021 500,466 ​ $ 16.81 7.36 $ — Granted 106,555 ​ $ 7.14 ​ ​ ​ Forfeited, expired and/or cancelled ​ (309,561) ​ $ 15.26 ​ ​ ​ ​ ​ Outstanding as of December 31, 2022 297,460 ​ $ 14.97 ​ 6.41 ​ $ — Exercisable as of December 31, 2022 257,216 ​ $ 15.85 6.59 $ — ​ ​ ​ ​ ​ ​ Outstanding Options by Plan ​ December 31, 2022 2010 Plan ​ ​ 116,571 2019 Plan ​ ​ 180,889 Outstanding as of December 31, 2022 ​ ​ 297,460 ​
2019 Stock plan
Schedule of stock option activity	The following table summarizes the activity of the 2019 Plan and the shares available for future equity awards as of December 31, 2022: ​ ​ ​ ​ ​ 2019 Plan ​ ​ ​ ​ Total shares reserved for equity awards as of December 31, 2021 ​ ​ 294,489 Options granted ​ (106,555) Forfeited, expired and/or cancelled equity option awards ​ ​ 184,132 Forfeited, expired and/or cancelled equity restricted stock awards ​ ​ 60,000 Shares forfeited to settle exercise price and tax obligation ​ ​ 9,234 Remaining shares available for future equity awards as of December 31, 2022 ​ ​ 441,300 ​

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Taxes
Schedule of Effective Income Tax Rate Reconciliation	​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, ​ ​ 2022 2021 Benefit at federal statutory rate (21.0) % (21.0) % State, net of federal income tax impact (4.0) % (4.4) % Stock-based compensation 4.0 % 0.1 % Registered offering gain/warrant expense (7.2) % (4.6) % Change in state deferred tax rate ​ 1.5 % 0.0 % Expiration of tax attribute carryforwards ​ 0.6 % 1.1 % Other ​ 0.0 % 2.1 % Change in valuation allowance 26.1 % 26.7 % Effective tax rate 0.0 % 0.0 % ​
Schedule of Deferred Tax Assets and Liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, ​ 2022 2021 Long-term deferred income tax assets (liabilities): ​ ​ Accrued liabilities ​ $ 3,000 ​ $ 96,000 Interest expense carryforward ​ ​ — ​ ​ 73,000 ROU asset ​ (18,000) ​ (155,000) Lease liability ​ ​ 150,000 ​ ​ 228,000 Net operating loss carryforward ​ 50,196,000 ​ 47,858,000 Share-based compensation ​ 459,000 ​ 1,050,000 Unrealized loss on trading security ​ 768,000 ​ 772,000 Property and equipment ​ 606,000 ​ 113,000 Warrants ​ 65,000 ​ 96,000 Capitalized development costs ​ ​ 2,093,000 ​ ​ — Asset retirement obligation ​ ​ 68,000 ​ ​ — Other ​ ​ 1,000 ​ ​ 1,000 Less: Valuation allowance ​ (54,391,000) ​ (50,132,000) Total long-term deferred income tax assets (liabilities) ​ $ — ​ $ — ​

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share
Schedule for the calculations of basic and diluted earnings per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 Net loss ​ $ (16,337,000) ​ $ (17,075,000) Less: decrease in fair value of investor warrants ​ ​ (5,761,000) ​ ​ (3,492,000) Net loss available to common stockholders ​ $ (22,098,000) ​ $ (20,567,000) ​ ​ ​ ​ ​ ​ ​ Basic weighted-average common shares outstanding ​ ​ 15,072,308 ​ ​ 13,286,605 Add: dilutive effect of equity instruments ​ ​ — ​ ​ 377,597 Diluted weighted-average shares outstanding ​ ​ 15,072,308 ​ ​ 13,664,202 Earnings per share – basic ​ $ (1.08) ​ $ (1.29) Earnings per share – diluted ​ $ (1.47) ​ $ (1.51) ​
Schedule of potentially dilutive securities, excluded	​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 Warrants to purchase shares of common stock 1,065,137 ​ 842,597 Outstanding stock options 297,460 ​ 500,466 Restricted stock awards 13,400 ​ 97,867 Total potentially dilutive shares of common stock 1,375,997 ​ 1,440,930

Basis of Presentation (Detail)

Basis of Presentation (Detail)	Nov. 09, 2022
Basis of Presentation
Stock split ratio	15

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Cash and Cash Equivalents (Detail) - USD ($)	Mar. 10, 2023	Dec. 31, 2022	Dec. 31, 2021
The Company and Summary of Significant Accounting Policies
Amount held in deposit account at SVB		$ 12,653,000	$ 33,892,000
SVB (Held as receivership by FDIC) | Subsequent Event
The Company and Summary of Significant Accounting Policies
Amount held in deposit account at SVB	$ 1,250,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Summary of Significant Accounting Policies
Long-lived assets impairment	$ 1,614,000	$ 0
Impairment charges on ROU assets	$ 322,000	$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Liquidity and Going Concern (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Summary of Significant Accounting Policies
Net loss	$ 16,337,000	$ 17,075,000
Operating expenses	22,318,000	20,571,000
Derivative gain	5,761,000	3,492,000
Interest income	220,000	4,000
Working capital	21,100,000
Accumulated deficit	233,939,000	217,602,000
Stockholders' equity	$ 11,789,000	$ 27,284,000	$ 17,516,000

Prepaid Expenses and Other (Det

Prepaid Expenses and Other (Detail) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Prepaid Expenses and Other
Unamortized commercial insurance premiums	$ 610,000	$ 465,000
Deposits	34,000	884,000
Professional fees	19,000	235,000
Clinical trial inventory		72,000
Other	13,000	84,000
Total prepaid expenses and other	$ 676,000	$ 1,740,000

Fixed Assets (Detail)

Fixed Assets (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years		10 years
Fixed assets, gross		$ 9,429,000	$ 10,798,000
Accumulated depreciation		(9,245,000)	(8,234,000)
Fixed assets, net		$ 184,000	2,564,000
Impairment loss	$ 1,600,000
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years		10 years
Fixed assets, gross		$ 4,965,000	6,075,000
Manufacturing facility/clean room [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross		$ 2,803,000	2,984,000
Manufacturing facility/clean room [Member] | Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years		3 years
Manufacturing facility/clean room [Member] | Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years		8 years
Lab equipment and office furniture
Property, Plant and Equipment [Line Items]
Fixed assets, gross		$ 1,661,000	$ 1,739,000
Lab equipment and office furniture | Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years		5 years
Lab equipment and office furniture | Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years		8 years

Fixed Assets - Depreciation Exp

Fixed Assets - Depreciation Expenses (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fixed Assets
Depreciation and amortization	$ 1,048,000	$ 1,094,000

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Detail) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Accounts Payable and Accrued Expenses
Accounts payable	$ 97,000	$ 427,000
Clinical trials	89,000	2,995,000
Professional fees	157,000	510,000
Commercial insurance premium financing	189,000	269,000
Accrued severance	143,000
Accrued compensation		389,000
Other	177,000	221,000
Accounts payable and accrued expenses	$ 852,000	$ 4,811,000

Accounts Payable and Accrued _4

Accounts Payable and Accrued Expenses - Commercial Insurance Premium Financing Agreement (Detail) - Commercial Insurance Premium Financing Agreement - USD ($)	1 Months Ended
	Jun. 30, 2022	Dec. 31, 2022
Debt Instrument [Line Items]
Financing agreement amount	$ 1,200,000
Term of agreement (in years)	8 months
Interest rate (as a percentage)	3.98%
Insurance down payment	$ 402,000
Principal and interest payments per month	$ 95,000
Outstanding obligation amount		$ 189,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)

1 Months Ended

12 Months Ended

Apr. 30, 2022 USD ($)

Apr. 04, 2022 installment

Feb. 04, 2022 USD ($)

Dec. 31, 2013 USD ($)

Dec. 31, 2022 USD ($) item

Dec. 31, 2021 USD ($)

Nov. 04, 2022 USD ($)

Sep. 30, 2022 USD ($)

Feb. 28, 2022 USD ($)

Jun. 30, 2021 USD ($)

Apr. 01, 2021 USD ($)

Mar. 31, 2021 USD ($)

Dec. 31, 2020 USD ($)

Commitments and Contingencies [Line Items]

Contract amount

$ 200,000

Cost of change orders

$ 700,000

Asset Retirement Obligations, Noncurrent

$ 289,000

$ 0

Facility Lease Incremental Borrowing Rate

5.75%

Right of use asset impairment

$ 322,000

0

Personal Service Agreement with Trauma Research LLC

Commitments and Contingencies [Line Items]

Contract amount

$ 250,000

Term of agreement

1 year

Number of equal quarterly installments | installment

4

Contractual obligation

$ 21,000

Sponsored Research Agreement with Trauma Research, LLC

Commitments and Contingencies [Line Items]

Contract amount

$ 400,000

Term of agreement

2 years

Contractual obligation

$ 63,000

Newly Leased Office Space and Manufacturing Facility

Commitments and Contingencies [Line Items]

Non-cancellable operating lease period

125 months

Lease renewal term

60 months

Lease initial base rent per month

$ 23,000

Rent expense

$ 3,300,000

New CRO

Commitments and Contingencies [Line Items]

Contract amount

$ 1,400,000

Contractual deposit Commitment

315,000

315,000

Contractual obligation

$ 0

$ 120,000

Intravenous treatment for COVID 19 patients

Commitments and Contingencies [Line Items]

Number of subjects under interim enrollment | item

35

Intravenous IV treatment for COVID 19 patients [Member]

Commitments and Contingencies [Line Items]

Contract amount

$ 1,800,000

Net Contractual Adjustment

$ 500,000

Contractual obligation

0

Revised contract amount

1,300,000

Regional Hospital Group, AP-018 Study

Commitments and Contingencies [Line Items]

Contract amount

$ 318,000

Contractual amendment

$ 946,000

Contractual obligation

0

$ 1,300,000

Regional Hospital Group, AP-019 Study

Commitments and Contingencies [Line Items]

Contract amount

$ 2,600,000

Contractual amendment

900,000

Contractual obligation

$ 0

$ 3,500,000

Commitments and Contingencies_2

Commitments and Contingencies - Employment Agreements (Detail) - USD ($)		9 Months Ended
	Aug. 30, 2022	Aug. 29, 2022
Mr. Daniel Stokely
Related Party Transaction [Line Items]
Annual Salary		$ 335,000
Mr. Michael A. Martino
Related Party Transaction [Line Items]
Annual Salary	$ 550,000

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Reconciliation of Company's Undiscounted Payments for Facility Lease and Carrying Amount of Lease Liability (Detail) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2023	$ 364,000
2024	280,000
Remaining Facility Lease Payments	644,000
Less: Discount Adjustment	(30,000)
Total lease liability	614,000
Lease liability - current portion	340,000	$ 311,000
Long-term lease liability	$ 274,000	$ 614,000

Commitments and Contingencies_4

Commitments and Contingencies - Lease Expense (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Litigation.
Balance as of December 31, 2021	$ 629,000
Amortization	(232,000)
Impairment loss	(322,000)	$ 0
Balance as of December 31, 2022	75,000	629,000
Lease expense	$ 311,000	$ 275,000

Warrants - Warrants Activity (D

Warrants - Warrants Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Number of Warrants Outstanding
Warrants outstanding	1,065,137	1,220,194
Number of Warrants Outstanding, Beginning Balance	1,220,194
Number of Warrants, Warrants expired	(155,057)
Number of Warrants Outstanding, Ending Balance	1,065,137	1,220,194
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 15.36
Weighted Average Exercise Price, Warrants Expired	11.40
Weighted Average Exercise Price, Outstanding Ending Balance	$ 15.94	$ 15.36
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Warrants Outstanding	3 years 9 months 18 days	4 years 2 months 26 days
Registered Direct Offering
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 16.50
Weighted Average Exercise Price, Outstanding Ending Balance		$ 16.50
Equity based-warrants
Number of Warrants Outstanding
Warrants outstanding	100,000
Number of Warrants Outstanding, Ending Balance	100,000
Liability warrants
Number of Warrants Outstanding
Warrants outstanding	1,000,000
Number of Warrants Outstanding, Ending Balance	1,000,000

Warrants - Warrants Activity Cl

Warrants - Warrants Activity Classified as Equity and Liability (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants Outstanding, Ending Balance	1,065,137	1,220,194
Exercise price	$ 15.94	$ 15.36
Weighted Average Remaining Contractual Life, Warrants Outstanding	3 years 9 months 18 days	4 years 2 months 26 days
Investor Warrants - December 2021 registered direct offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants Outstanding, Ending Balance	1,000,000
Exercise price	$ 16.50
Weighted Average Remaining Contractual Life, Warrants Outstanding	3 years 11 months 15 days
Investor Warrants, August 2018 public offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants Outstanding, Ending Balance	10,227
Exercise price	$ 6
Weighted Average Remaining Contractual Life, Warrants Outstanding	7 months 9 days
Placement Agent, June 2019 Public offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants Outstanding, Ending Balance	54,910
Exercise price	$ 7.50
Weighted Average Remaining Contractual Life, Warrants Outstanding	1 year 5 months 15 days

Warrants - Narrative (Detail)

Warrants - Narrative (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2022	Dec. 15, 2021	Aug. 31, 2018	Jun. 30, 2017
Class of Warrant or Right [Line Items]
Warrant derivative liability	$ 5,805,000	$ 44,000
Exercise price	$ 15.36	$ 15.94
Investor Warrants
Class of Warrant or Right [Line Items]
Proceeds from warrant exercises	$ 114,000
Number Of Warrants Exercised By Placement Agents	35,249
Stock Issued On Exercise Of Warrants By Placement Agents	20,275
Warrants exercised, net (Shares)	18,940
Exercise price	$ 6
Confidentially Marketed Public Offering | 2018 public offerings
Class of Warrant or Right [Line Items]
Warrants to purchase common stock, shares				1,300,000
Warrant, Term	1 year 7 months 9 days	7 months 9 days		5 years
Warrants outstanding, Fair value	$ 52,000	$ 0
Warrant derivative liability	$ 52,000
Exercise price				$ 6
Registered Direct Offering
Class of Warrant or Right [Line Items]
Warrants to purchase common stock, shares	1,000,000
Warrant, Term	5 years
Exercise price	$ 16.50
Registered Direct Offering | 2017 public offering
Class of Warrant or Right [Line Items]
Warrants to purchase common stock, shares					733,334
Warrant, Term		5 months 1 day			5 years
Warrants outstanding, Fair value					$ 156,000
Warrant derivative liability		$ 156,000
Exercise price					$ 11.40
Registered Direct Offering | 2021 public offering
Class of Warrant or Right [Line Items]
Warrants to purchase common stock, shares			1,000,000
Warrant, Term	4 years 11 months 15 days	3 years 11 months 15 days	5 years
Fair value of warrants	$ 5,600,000	$ 44,000,000
Warrant derivative liability	$ 5,597,000	$ 44,000
Exercise price			$ 16.50

Warrants - Assumptions for Warr

Warrants - Assumptions for Warrants Issued (Detail)	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 15, 2021	Aug. 31, 2018	Jun. 30, 2017
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Number of shares | shares	1,065,137	1,220,194
Derivative liability | $	$ 44,000	$ 5,805,000
Registered Direct Offering
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants term (Years)		5 years
2018 public offerings | Confidentially Marketed Public Offering
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants term (Years)	7 months 9 days	1 year 7 months 9 days		5 years
Number of shares | shares	10,227	10,227
Derivative liability | $		$ 52,000
2018 public offerings | Confidentially Marketed Public Offering | Exercise Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input | $ / shares	6	6
2018 public offerings | Confidentially Marketed Public Offering | Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	2	1.07
2018 public offerings | Confidentially Marketed Public Offering | Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0.0475	0.0060
2017 public offering | Registered Direct Offering
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants term (Years)	5 months 1 day				5 years
Number of shares | shares	135,128
Derivative liability | $	$ 156,000
2017 public offering | Registered Direct Offering | Exercise Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input | $ / shares	11.40
2017 public offering | Registered Direct Offering | Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0.92
2017 public offering | Registered Direct Offering | Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0.0015
2021 public offering | Registered Direct Offering
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants term (Years)	3 years 11 months 15 days	4 years 11 months 15 days	5 years
Number of shares | shares	1,000,000	1,000,000
Derivative liability | $	$ 44,000	$ 5,597,000
2021 public offering | Registered Direct Offering | Exercise Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input | $ / shares	16.50	16.50
2021 public offering | Registered Direct Offering | Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	121	101
2021 public offering | Registered Direct Offering | Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	4.11	1.25

Fair Value Considerations - Fin

Fair Value Considerations - Financial Assets and Liabilities (Detail) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
LIABILITIES
Warrant derivative liability	$ 44,000	$ 5,805,000
Fair Value, Inputs, Level 3
LIABILITIES
Warrant derivative liability	$ 44,000	$ 5,805,000

Fair Value Considerations - Set

Fair Value Considerations - Sets Forth a Reconciliation of Changes (Detail)	12 Months Ended
	Dec. 31, 2022 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Beginning balance	$ 5,805,000
Change in fair value	$ (5,761,000)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Gain (Loss) on Derivative Instruments, Net, Pretax
Ending balance	$ 44,000

Common Stock - Summarizes the C

Common Stock - Summarizes the Company's remaining authorized shares available (Detail) - shares	Dec. 31, 2022	Dec. 31, 2021
Common Stock.
Authorized shares	300,000,000	300,000,000
Common stock outstanding	15,102,877	15,172,111
Options outstanding	297,460
Warrants outstanding	1,065,137	1,220,194
Reserved for issuance under 2019 Stock and Incentive Plan	441,300
Available shares for future issuance	283,093,226

Common Stock - Registered Direc

Common Stock - Registered Direct Offering Narrative (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended
	Dec. 31, 2021	Dec. 31, 2022
Components of common Stock [Line Items]
Exercise price (Dollars per share)	$ 15.36	$ 15.94
Registered Direct Offering
Components of common Stock [Line Items]
Issuance of common stock in connection with the public offering (in shares)	1,670
Stock price (in dollars per share)	$ 13.50
Warrants to purchase common stock, shares	1,000
Proceeds from issuance of common stock	$ 22,500
Percentage of commission	7%
Underwriter commission	$ 1,600
Compensation for other costs relating To offering	75
Costs associated with the offering	$ 167
Exercise price (Dollars per share)	$ 16.50
Warrants term (Years)	5 years
Warrants Outstanding	$ 6,700

Common Stock - Sales Agreement

Common Stock - Sales Agreement (Detail) $ in Millions	1 Months Ended	12 Months Ended
	Feb. 29, 2020 USD ($) item	Dec. 31, 2021 USD ($) shares
Sale Agreement (ATM)
Class of Stock [Line Items]
Number of agents | item	2
Maximum aggregate offering price of equity securities	$ 50
Percentage of commission	4%
ATM Equity Offering Program
Class of Stock [Line Items]
Number of common stock shares issued | shares		416,406
Proceeds from issuance of common stock		$ 10
Placement agent commissions and issuance costs		$ 0.5
Sales Agreement Agent [Member] | Sale Agreement (ATM)
Class of Stock [Line Items]
Percentage of commission	2%

Common Stock - Common Stock Iss

Common Stock - Common Stock Issued for Services (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Components of common Stock [Line Items]
Issuance of common stock for services		$ 80
Common Stock Issued for Services | Non Employee Directors [Member]
Components of common Stock [Line Items]
Issuance of common stock for services (Shares)	0	3,604
Issuance of common stock for services		$ 80

Equity Instruments - Activity o

Equity Instruments - Activity of Plan (Detail)		12 Months Ended
	Nov. 09, 2022 shares	Dec. 31, 2022 shares	Dec. 31, 2021 shares	Dec. 31, 2019 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock split ratio	15
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted		(106,555)
Forfeited, expired and/or cancelled equity awards		309,561
Restricted Stock [Member
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards granted		(119,000)
2019 Stock plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for equity awards as of December 31, 2021	666,667
Stock split ratio	15
2019 Stock plan | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for equity awards as of December 31, 2021			294,489	10,000,000
Options granted		(106,555)
Forfeited, expired and/or cancelled equity awards		184,132
Shares forfeited to settle exercise price and tax obligation		9,234
Remaining shares available for future equity awards as of December 31, 2022		441,300
2019 Stock plan | Restricted Stock [Member
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeited, expired and/or cancelled equity awards		60,000

Equity Instruments - Stock Opti

Equity Instruments - Stock Option Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Number of Options
Number of Options, Ending Balance	297,460
Employee Stock Option
Number of Options
Number of Options, Beginning Balance	500,466
Number of Options, Granted	106,555
Number of Options, Forfeited, expired and/or cancelled	(309,561)
Number of Options, Ending Balance	297,460	500,466
Number of Options, Exercisable	257,216
Weighted Average Exercise Price
Weighted Average Exercise Price, Beginning Balance	$ 16.81
Weighted Average Exercise Price, Granted	7.14
Weighted Average Exercise Price, Forfeited, expired and/or cancelled	15.26
Weighted Average Exercise Price, Ending Balance	14.97	$ 16.81
Weighted Average Exercise Price, Exercisable	$ 15.85
Weighted Average Remaining Contractual Life, Outstanding	6 years 4 months 28 days	7 years 4 months 9 days
Weighted Average Remaining Contractual Life, Exercisable	6 years 7 months 2 days
2010 Stock Plan
Number of Options
Number of Options, Ending Balance	116,571
2019 Stock plan
Number of Options
Number of Options, Ending Balance	180,889
2019 Stock plan | Employee Stock Option
Number of Options
Number of Options, Granted	106,555
Number of Options, Forfeited, expired and/or cancelled	(184,132)

Equity Instruments - Summary of

Equity Instruments - Summary of Stock Options Outstanding and Exercisable (Detail)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	297,460
Weighted Average Exercise Price	$ 14.97
Weighted Average Remaining Contractual Lives	6 years 4 months 28 days
Up to $7.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	63,457
Weighted Average Exercise Price	$ 6.67
Weighted Average Remaining Contractual Lives	3 years 8 months 23 days
Range of Exercise Prices Lower	$ 7.50
$7.51 - $15.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	140,327
Weighted Average Exercise Price	$ 10.39
Weighted Average Remaining Contractual Lives	6 years 5 months 12 days
Range of Exercise Prices Lower	$ 7.51
Range of Exercise Prices Upper	$ 15
$15.01 - $22.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	53,600
Weighted Average Exercise Price	$ 17.30
Weighted Average Remaining Contractual Lives	8 years 9 months 29 days
Range of Exercise Prices Lower	$ 15.01
Range of Exercise Prices Upper	$ 22.50
$22.51 and above
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	40,076
Weighted Average Exercise Price	$ 40.98
Weighted Average Remaining Contractual Lives	7 years 3 months 21 days
Employee Stock Option | $22.51 and above
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices Lower	$ 22.51

Equity Instruments - Restricted

Equity Instruments - Restricted Stock Awards (Details) - Restricted Stock [Member	12 Months Ended
	Dec. 31, 2022 employee $ / shares shares	Oct. 31, 2021 agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of employment agreements | agreement		3
Number of employee authorized to withhold share of common stock | employee	3
Number of shares forfeiture	9,234
Shares issued in connection with restricted stock awards	15,233
Awards
Unvested as of beginning	97,867
Granted (Shares)	119,000
Forfeited (Shares)	(60,000)
Vested (Shares)	(24,467)
Unvested at ending	13,400
Average Grant-Date Fair Value
Unvested at beginning (Dollars per share) | $ / shares	$ 24.60
Vested (Dollars per share) | $ / shares	24.60
Unvested at ending (Dollars per share) | $ / shares	$ 24.60

Equity Instruments - Assumption

Equity Instruments - Assumptions Used in Computing Fair Value of All Options Granted (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, Minimum	116.83%	113%
Expected volatility, Maximum	119.43%	127%
Risk free interest rate, Minimum	1.26%	0.78%
Risk free interest rate, Maximum	1.94%	1.38%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years 5 months 12 days	5 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years 6 months 3 days	6 years 6 months

Equity Instruments - Summary _2

Equity Instruments - Summary of Stock-Based Compensation Expense (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation, net of forfeitures	$ 953,000	$ 2,804,000
Unrecognized share-based compensation expense related to stock options as of December 31, 2022	$ 185,000
Weighted average remaining years to vest for stock options	1 year 5 months 1 day
Unrecognized share-based compensation expense related to restricted stock awards as of December 31, 2022	$ 116,000
Weighted average remaining years to vest for restricted stock awards	2 years 3 days
Research and Development Expenses | Share-Based Payment Arrangement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation, net of forfeitures	$ 139,000	46,000
General and Administrative Expenses | Common Stock Issued for Services
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation, net of forfeitures		80,000
General and Administrative Expenses | Share-Based Payment Arrangement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation, net of forfeitures	$ 814,000	$ 2,678,000

Equity Instruments - Additional

Equity Instruments - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance	441,300
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 15.94	$ 15.36
Allocated Share-based Compensation Expense	$ 953,000	$ 2,804,000
Class of Warrant or Right, Outstanding	1,065,137	1,220,194
Common Stock, Shares, Issued	15,102,877	15,172,111
Restricted Stock [Member
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 500,000
Reversals for non-vested shares for director and employee forfeitures	$ 500,000
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	106,555
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 7.14
Allocated Share-based Compensation Expense	$ 1,100,000
Reversals for non-vested shares for director and employee forfeitures	$ 200,000
Options, Exercise Price per share	$ 14.97	$ 16.81
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	309,561
Registered Direct Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 16.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,000,000
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		25,774

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Taxes
Benefit at federal statutory rate	(21.00%)	(21.00%)
State, net of federal income tax impact	(4.00%)	(4.40%)
Stock-based compensation	4%	0.10%
Registered offering gain / warrant expense	(7.20%)	(4.60%)
Change in state deferred tax rate	1.50%	0%
Expiration of tax attribute carryforwards	0.60%	1.10%
Other	0%	2.10%
Change in valuation allowance	26.10%	26.70%
Effective tax rate	0%	0%

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Liabilities (Detail) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Long-term deferred income tax assets (liabilities):
Accrued liabilities	$ 3,000	$ 96,000
Interest expense carryforward		73,000
ROU Asset	(18,000)	(155,000)
Lease liability	150,000	228,000
Net operating loss carryforward	50,196,000	47,858,000
Share-based compensation	459,000	1,050,000
Unrealized loss on trading security	768,000	772,000
Property and equipment	606,000	113,000
Warrants	65,000	96,000
Capitalized development costs	2,093,000
Asset retirement obligation	68,000
Other	1,000	1,000
Less: Valuation allowance	(54,391,000)	(50,132,000)
Total long-term deferred income tax assets (liabilities)	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Income Taxes [Line Items]
Operating Loss Carryforwards	$ 205
Operating Loss Carryforward, Carries Forward Indefinitely	$ 74.5
Minimum
Income Taxes [Line Items]
Percentage Of Likelihood Of Tax Benefit Being Realized	50%

Earnings Per Share (Detail)

Earnings Per Share (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share
Net loss	$ (16,337,000)	$ (17,075,000)
Less: decrease in fair value of investor warrants	(5,761,000)	(3,492,000)
Net loss available to common stockholders	$ (22,098,000)	$ (20,567,000)
Basic weighted-average common shares outstanding	15,072,308	13,286,605
Add: dilutive effect of equity instruments		377,597
Diluted weighted-average shares outstanding	15,072,308	13,664,202
Earnings per share - basic	$ (1.08)	$ (1.29)
Earnings per share - diluted	$ (1.47)	$ (1.51)

Earnings Per Share - Anti-dilut

Earnings Per Share - Anti-dilutive (Detail) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares of common stock	1,375,997	1,440,930
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares of common stock	1,065,137	842,597
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares of common stock	297,460	500,466
Restricted Stock [Member
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares of common stock	13,400	97,867

Litigation (Details)

Litigation (Details) - item	Nov. 07, 2022	Nov. 02, 2022	Oct. 25, 2022	Oct. 17, 2022	Oct. 07, 2022	Aug. 17, 2022
Kain v. Ampio Pharmaceuticals, Inc., et al., 22-cv-2105
Loss Contingencies [Line Items]
Number of former executives against whom a securities fraud class action has been filed						2
Number of putative shareholders who filed motions seeking to be named lead plaintiff				6
Number of movants filed oppositions to each other's motions	2
Maresca v. Martino, et al., 22-cv-2646-KLM
Loss Contingencies [Line Items]
Number of defendants who are in violation of the Company's insider trading restrictions					2
Number of causes of action as asserted by the Complaint					6
Number of derivative actions to be consolidated		2
Marquis v. Martino, et al., 22-cv-2803-KLM
Loss Contingencies [Line Items]
Number of causes of action as asserted by the Complaint		2
Number of derivative actions to be consolidated			2
Number of plaintiffs appointed as co-lead counsel		2

Employee Benefit Plan (Detail)

Employee Benefit Plan (Detail)	12 Months Ended
	Dec. 31, 2022 USD ($)
Employee Benefit Plan
Matching employee contributions provided by the company	$ 67,000